



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

# Best of ASTRO 2016

## Czech Republic

20. 3. 2017

Kongresové centrum Kunětická Hora Dříteč





SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

09:30-10:10

### Track 1 - Gastrointestinal

Renata Soumarova, Ass. Prof. (Oncology Centre Novy Jicin, Agel)

**Abstract 1: (9755)** The Initial Results for a Phase 3 Study of Short-term Versus Long-term Chemoradiation Therapy in Locally Advanced Rectal Cancer (STELLAR Trial)

**Abstract 2: (12610)** Phase 1 Study of Trametinib and Neoadjuvant Chemoradiation (CRT) in Locally Advanced Rectal Cancer (LARC) with KRAS, BRAF or NRAS Mutations

**Abstract 3: (11923)** Impact of Radiation Dose Escalation for Cervical Esophageal Cancer: A National Cancer Data Base (NCDB) Analysis

**Abstract 4: (9812)** A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared with Chemoradiation Therapy in Locally Advanced Gastroesophageal and Gastric Adenocarcinoma: Preliminary Results

**Abstract 5: (11343)** Patient-reported Outcomes (PROs) in NRG Oncology/RTOG 0436: A Phase 3 Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin and Radiation for Esophageal Cancer Treated without Surgery

**Abstract 6: (8760)** Prospective Randomized Phase 2 Study of Concurrent Chemoradiation Therapy (CCRT) Versus Chemotherapy Alone in Stage IV Esophageal Squamous Cell Carcinoma (ESCC)

**Abstract 7: (11407)** Combined Analysis of Two Prospective Trials of Individualized Adaptive Stereotactic Body Radiation Therapy for the Treatment of Hepatocellular Carcinoma (HCC) or Liver Metastases

**Abstract 8: (12535)** Protocol RAD 0902: A Pilot Study of Transarterial Chemoembolization Followed by Stereotactic Radiation Therapy for Locally Advanced Hepatocellular Carcinoma



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

10:10-10:50

## Track 2 - Gynecological

Martina Kubecova, Ass. Prof. (Department of Oncology, University Hospital Kralovske Vinohrady, Prague)

**Abstract 1: (11646)** A Phase 3 Randomized Trial Comparing Patient-reported Toxicity and Quality of Life (QOL) During Pelvic Intensity Modulated Radiation Therapy as Compared to Conventional Radiation Therapy

**Abstract 2: (8607)** Phase 3 Randomized Trial of Comparing Chemoradiation Therapy Versus Radiation Therapy Alone in Lymph Node–negative Patients With Early-stage Cervical Cancer Following Radical Hysterectomy

**Abstract 3: (10421)** Nodal Failure After Chemoradiation and Magnetic Resonance Imaging Guided Adaptive BT in Cervical Cancer: A Subanalysis Within Embrace

**Abstract 4: (7909)** Phase 2 Multicenter Clinical Trial of Bone Marrow–sparing Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage IB-IVA Cervical Cancer

**Abstract 5: (10055)** Computed Tomography Consensus Clinical Target Volume Contouring for Intensity Modulated Radiation Therapy in Intact Cervical Carcinoma

**Abstract 6: (10547)** National Cancer Data Base Analysis of Uterine Carcinosarcoma (UC): Improvement in Survival With the Use of Radiation Therapy

**Abstract 7: (9670)** Updated 4-Year Results for NRG Oncology/RTOG 0921: A Phase 2 Study of Postoperative Intensity Modulated Radiation Therapy With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer

**Abstract 8: (10280)** Implication of Adjuvant Radiation Therapy and Dose-Response Relationship for Margin-positive Vulvar Squamous Cell Carcinoma

**Abstract 9: (11633)** Impact of Cumulative Radiation Doses to Vagina on Late Toxicity and Sexual Quality of Life in Patients Treated With Postoperative Adjuvant Radiation Therapy for Cervical Cancer



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

11:00-11:40

### Track 3 - Genitourinary

Karel Odrázka, Prof. (Oncology Centre Multiscan, Pardubice)

**Abstract 1: (11006)** Initial Report of NRG Oncology/ RTOG 0232: A Phase 3 Study Comparing Combined External Beam Radiation and Transperineal Interstitial Permanent Brachytherapy with Brachytherapy Alone for Selected Patients with Intermediate-risk Prostatic Carcinoma

**Abstract 2: (9839)** NRG Oncology/RTOG 0415, Phase 3 Non-inferiority Study Comparing Two Fractionation Schedules in Patients with Low-risk Prostate Cancer: Prostate-specific Quality of Life Results

**Abstract 3: (8550)** Randomized Trial of Hypofractionated Dose-escalated Intensity Modulated Radiation Therapy Versus Conventionally Fractionated Intensity Modulated Radiation Therapy for Localized Prostate Cancer

**Abstract 4: (12762)** Five-year Outcomes from a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-risk Prostate Cancer

**Abstract 5: (7936)** Long-term Androgen Deprivation, with or without Radiation Therapy, in Locally Advanced Prostate Cancer: Results from a Phase 3 Randomized Study After 7.3 Years Median Follow-up

**Abstract 6: (8782)** Androgen Deprivation and High-dose Radiation Therapy in Prostate Cancer: Report on Late Toxicity from DART 01/05 Randomized Phase III Trial

**Abstract 7: (10807)** Staging of Biochemically Relapsing Prostate Cancer Using the Positron Emission Tomography Tracer Fluciclovine F18

**Abstract 8: (10451)** Prostate Cancer-specific Mortality and Survival Outcomes for Salvage Radiation Therapy After Radical Prostatectomy



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

11:40-12:20

## **Track 4 - Oropharyngeal Guideline and APBI Consensus Update**

Martin Dolezel, Ass. Prof. (Oncology Centre Multiscan, Pardubice)

### **Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: An ASTRO Evidence-Based Clinical Practice Guideline**

1. When is it appropriate to add systemic therapy to radiotherapy in the treatment of intact oropharyngeal squamous cell carcinoma (OPSCC)?
2. When is it appropriate to deliver post-operative radiotherapy with and without systemic therapy following primary surgery of OPSCC?
3. When is it appropriate to use induction chemotherapy in the treatment of OPSCC?
4. What are the appropriate dose, fractionation and volume regimens with and without chemotherapy in the treatment of OPSCC?

### **Accelerated Partial Breast Irradiation (APBI): An Update of an ASTRO Evidence-Based Consensus Statement**

1. Lowering the suitability age to 50 instead of 60.
2. Adding low risk ductal carcinoma in situ (DCIS) to the suitable category.
3. Providing novel guidance to ASTRO membership on appropriate adoption of intraoperative radiation therapy (IORT) into clinical practice.



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

12:20-13:00

### Track 5 - Breast

Jiri Petera, Prof. (Department of Oncology, Faculty Hospital Hr. Kralove)

**Abstract 1: (8537)** Radiation Boost for Ductal Carcinoma In Situ After Whole-breast Radiation Therapy (WBRT) Improves Local Control: Analysis From 10 Pooled Academic Institutions

**Abstract 2: (10880)** Efficacy of Mometasone Furoate in the Reduction of Moderate/Severe Radiation Dermatitis in Breast Cancer Patients Following Mastectomy

**Abstract 3: (9294)** Longitudinal Analysis of Patient-reported Outcomes and Cosmesis in a Randomized Trial of Conventionally Fractionated Versus Hypofractionated Whole-breast Irradiation

**Abstract 4: (11056)** The Effect of Breast Irradiation on Cardiac Disease in Women Enrolled on BCIRG-001 at 10-Year Follow-up

**Abstract 5: (12708)** Regional Patterns of Breast Cancer Failure After Definitive Therapy: A Large, Single-institution Analysis

**Abstract 6: (10934)** The 21-Gene Recurrence Score and Locoregional Recurrence Rates in Patients with Node-positive Breast Cancer Treated on SWOG S8814

**Abstract 7: (11657)** CD47 as a Target for Immune-radiation Therapy for HER2-Expressing Breast Cancer Cells

**Abstract 8: (10231)** Ten-year Results of the Breast Intensity Modulated Radiation Therapy (IMRT) Randomized Controlled Trial



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

14:00-14:40

## Track 6 - Head and Neck

Milan Vosmik, PhD (Department of Oncology, Faculty Hospital Hr. Kralove)

**Abstract 1: (10719)** Concurrent Chemoradiation Therapy Versus Acceleration of Radiation Therapy with or without Concurrent Chemotherapy in Locally Advanced Head and Neck Carcinoma (GORTEC 99-02): Seven-year Survival Data from a Phase 3 Randomized Trial and Prognostic Factors

**Abstract 2: (11726)** Intensity Modulated Radiation Therapy Versus 3-Dimensional Conformal Radiation Therapy in Head and Neck Squamous Cell Carcinoma: A Pooled Analysis of NRG Oncology/ RTOG 0129 and 0522

**Abstract 3: (7954)** Radiation Therapy Variation in the Randomized Phase 3 Positron Emission Tomography Neck Study

**Abstract 4: (11494)** Multi-institution Analysis of Intensity Modulated Radiation Therapy-based Reirradiation for Head and Neck Cancer: Prognostic Factors and Recursive Partitioning Analysis for Overall Survival

**Abstract 5: (11384)** Optimal Treatment Selection of Stereotactic Body Radiation Therapy and Intensity Modulated Radiation Therapy for Reirradiation of Head and Neck Cancer: A Multi-institution Comparison

**Abstract 6: (11896)** Multi-institution Analysis of Intensity Modulated Radiation Therapy-based Reirradiation for Head and Neck Cancer: Improved Risk-benefit Profile in the Modern Era

**Abstract 7: (11685)** Phase 2 Trial of Induction Chemotherapy Followed by Attenuated Chemoradiation Therapy for Human Papillomavirus-positive Locally Advanced Squamous Cell Carcinoma of the Oropharynx

**Abstract 8: (12761)** Cetuximab-Based Bioradiation Therapy Versus Cisplatin-based Chemoradiation Therapy in the Definitive Treatment of Locally Advanced Oropharyngeal Squamous Cell Carcinoma



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

14:40-15:20

## Track 7 - Lung

David Feltl, Ass. Prof. (Department of Oncology, Faculty Hospital Ostrava)

**Abstract 1: (8415)** Efficacy and Toxicity Analysis of NRG Oncology/RTOG 0813 Trial of Stereotactic Body Radiation Therapy (SBRT) for Centrally Located Non-small Cell Lung Cancer (NSCLC)

**Abstract 2: (9471)** A Phase 2 Randomized Study of two Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients with Node-negative, Peripheral Non-small Cell Lung Cancer

**Abstract 3: (9460)** Impact of Incidental Cardiac Radiation on Cardiopulmonary Toxicity and Survival for Locally Advanced Non-small Cell Lung Cancer: Reanalysis of NRG Oncology/RTOG 0617 with Centrally Contoured Cardiac Structures

**Abstract 4: (9437)** Safety of Dose Escalation by Simultaneous Integrated Boosting Radiation Dose in Unresectable Stage III Non-small Cell Lung Cancer

**Abstract 5: (12343)** Radiation Dose to the Thoracic Vertebral Bodies is Associated with Acute Hematologic Toxicity in Patients Receiving Concurrent Chemoradiation for Lung Cancer

**Abstract 6: (8088)** Identifying Patients with Extensive-stage Small Cell Lung Cancer (ES-SCLC) Most Likely to Benefit from Intensive Radiation Therapy

**Abstract 7: (10285)** The Differential Impact of Postoperative Radiation Therapy for Completely Resected Stage IIIA(N2) Non-small Cell Lung Cancer: Based on the Risk Prediction Model for Locoregional Recurrence

**Abstract 8: (9088)** Role of Surveillance Imaging Versus Symptoms and Signs in Detection of Recurrence of Non-small Cell Lung Cancer After Curative Intent Therapy



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

15:30-16:10

### Track 8 – Central Nervous System

Pavel Slampa, Prof., Tomas Kazda, Dr (Department of Radiation Oncology, MMCI, Brno)

**Abstract 1: (11991)** Deferring Radiation Therapy for Brain Metastases in Patients with EGFR-mutant Non-small Cell Lung Cancer: A Multi-institutional Analysis

**Abstract 2: (9559)** Treatment of Cerebral Radiation Necrosis with Nerve Growth Factor—A Prospective, Randomized, Controlled Phase 2 Study

**Abstract 3: (8991)** Omission of Radiation Therapy for Low-grade Gliomas: Molecular and Radiographic Correlates of Treatment Response and Disease Progression on a Phase 2 Clinical Trial of Adjuvant Temozolomide

**Abstract 4: (11889)** Hippocampal Dosimetry Predicts for Cancer-related Cognitive Impairment in Patients Treated With Cranial Radiation Therapy: Dosimetric Results of a Prospective Clinical Trial

**Abstract 5: (9336)** Postoperative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study

**Abstract 6: (11381)** Mibefradil Dihydrochloride with Hypofractionated Radiation for Recurrent Glioblastoma: Preliminary Results of a Phase 1 Dose Expansion Trial

**Abstract 7: (12187)** Multi-institutional Competing Risks Analysis Predicting Distant Brain Failure and Salvage Patterns After Upfront Radiosurgery without Whole-Brain Radiation Therapy for Brain Metastasis

**Abstract 8: (8673)** Does Whole-brain Radiation Therapy for Oligometastatic Brain Metastases Translate into a Survival Benefit for Patients with a Limited Competing Risk from Extracranial Disease? A Secondary Analysis of EORTC 22952-26001



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

16:10-16:50

### Track 9 – Physics

Petr Paluska, PhD (Department of Oncology, Faculty Hospital Hr. Kralove)

**Abstract 1: (11670)** Reinforcement Learning Strategies for Decision Making in Knowledge-based Adaptive Radiation Therapy: Application in Liver Cancer

**Abstract 2: (8129)** Selection of FDG Positron Emission Tomography-based Bioparametric Matrixes for Tumor Dose Response Mapping and Adaptive Dose Painting by Number

**Abstract 3: (11039)** Apparent Diffusion Coefficients (ADCs) in Diffusion-weighted 3.0 Tesla MR Imaging is Useful in Predicting Therapeutic Response to Concurrent Chemoradiation Therapy in Patients with Uterine Cervical Cancer: A Prospective Study

**Abstract 4: (10095)** First Clinical Implementation of Electromagnetic Transponder-guided MLC Tracking for Lung Stereotactic Ablative Radiation Therapy

**Abstract 5: (9073)** Detection of Local Cancer Recurrence After Stereotactic Ablative Radiation Therapy (SABR) for Lung Cancer: Physician Performance Versus Radiomic Assessment



SCIENCE OF TODAY  
HOPE FOR TOMORROW

CZECH REPUBLIC

**Contact:** [bestof@multiscan.cz](mailto:bestof@multiscan.cz), [dolezelm@email.cz](mailto:dolezelm@email.cz)

Doc. MUDr. Martin Doležel, Ph.D.  
KOC Pardubického kraje, Kyjevská 44,  
532 03 Pardubice  
[www.multiscan.cz](http://www.multiscan.cz)

Kongresové centrum Kunětická Hora Dříteč  
Dříteč 155, 533 05  
GPS: 50°6'41.669"N, 15°49'9.128"E  
<http://grkh.cz/kongres/>

Vzdělávací akce je pořádána dle:  
- Stavovského předpisu ČLK č. 16 (6 kreditů)  
- §2 odst. f) vyhlášky č. 423/2004 Sb. ve znění vyhlášky 4/2010 Sb., (4 kredity)

Výše účastnického poplatku je 150 Kč (platba na místě).

**Prosím o elektronické přihlášení na e-mail [dolezelm@email.cz](mailto:dolezelm@email.cz)  
či [bestof@multiscan.cz](mailto:bestof@multiscan.cz) nejpozději do 10. 3. 2017.**